Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
01:23pm, Wednesday, 27'th Nov 2024
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
12:10pm, Wednesday, 13'th Nov 2024
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
02:02pm, Tuesday, 12'th Nov 2024
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Ni
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
01:17pm, Tuesday, 12'th Nov 2024
Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axso
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Tuesday, 12'th Nov 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago.
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11:50am, Monday, 11'th Nov 2024
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
07:00am, Friday, 08'th Nov 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:05am, Tuesday, 05'th Nov 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
07:00am, Tuesday, 29'th Oct 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
07:30am, Saturday, 19'th Oct 2024
Yes, bargains can still be found in the stock market.
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
07:00am, Tuesday, 15'th Oct 2024
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
10:40am, Friday, 11'th Oct 2024
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
1 Under-the-Radar Biotech Stock to Buy and Hold
07:32am, Sunday, 29'th Sep 2024
Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions.
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
12:35pm, Thursday, 05'th Sep 2024
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
12:35pm, Wednesday, 04'th Sep 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
